Avaí Bio and Austrianova Begin Production of Master Cell Bank for Klotho Anti-Aging Therapy Under GMP Standards
MWN-AI** Summary
Avaí Bio, Inc. (OTCQB: AVAI), a biotechnology firm focused on cell-based therapies for diabetes and age-related disorders, has announced a significant milestone in collaboration with Austrianova, a global biotechnology leader. They have officially commenced production of a Master Cell Bank (MCB) of genetically modified cells that overexpress the Klotho protein, known for its anti-aging properties. This initiative is part of their joint venture, Klothonova, aimed at developing innovative therapies to combat age-related diseases.
The production of the MCB is crucial as it complies with Good Manufacturing Practices (GMP) standards, ensuring a reliable source of cells for scale-up and production of effective cell therapies. A well-maintained MCB minimizes risks related to contamination and genetic instability, ultimately supporting the quality and consistency of future products. These cells will serve as the foundational resource for producing the Cell-in-a-Box® encapsulated cell product, specifically targeting conditions such as Alzheimer's and cancer and promoting longevity.
Chris Winter, CEO of Avaí Bio, emphasized the significance of this production phase in delivering safe and effective treatments for aging-related conditions. Austrianova's chairman, Prof. Walter H. Gunzburg, highlighted that establishing the MCB is essential for sustainable production and maintaining high-quality standards for their encapsulated cell products.
This partnership builds upon the JV agreement signed in September 2025, which officially established Klothonova in Nevada, equally owned by Avaí and Austrianova’s affiliate, SG Austria Pte. Ltd. Through this venture, both companies strive to harness the therapeutic potential of the Klotho protein to enhance healthspan and longevity. For more information on Avaí and its initiatives, visit their website.
MWN-AI** Analysis
Avaí Bio, Inc. (OTCQB: AVAI) recently announced a significant milestone in their collaboration with Austrianova—the production initiation of a Master Cell Bank (MCB) for their Klotho anti-aging therapy. This development marks a foundational step toward the commercial viability of their cell-based therapies targeting age-related diseases. The establishment of the MCB under GMP (Good Manufacturing Practices) standards ensures consistent quality and reliability, crucial for prospective scaling and market acceptance.
Investors should view this advancement as a positive indicator of Avaí's capacity to meet regulatory requirements and maintain quality control in a highly scrutinized sector. The partnership with Austrianova is essential, given their expertise in cell encapsulation and the development of GMP-grade cell products. This relationship positions Avaí strongly within the biotech space, particularly in the competitive anti-aging market, which is gaining traction with increasing consumer awareness of longevity and wellness.
Avaí's focus on the Klotho protein—a biomarker associated with longevity—places it at the forefront of a growing field of research aimed at age-related interventions. With increasing investment in biotechnology and a broader societal emphasis on aging solutions, Avaí Bio could be poised for growth as clinical applications of Klotho therapy advance. However, potential investors should consider the inherent risks associated with biotechnology stocks, including development timelines, regulatory challenges, and market competition.
In conclusion, while Avaí Bio's recent developments position it well for future growth opportunities, investors should remain cautious and perform due diligence. Monitoring clinical results from the Klotho program, along with updates on regulatory approvals, will be critical in assessing the potential impact on stock performance. As the market for anti-aging therapies expands, Avaí’s strategic initiatives may provide attractive investment opportunities for those willing to navigate the high-risk biotech landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Canada NewsWire
LAS VEGAS, March 3, 2026 /CNW/ -- Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced--together with its joint venture partner and global biotechnology firm, Austrianova--the initiation of production for a Master Cell Bank of genetically modified cells that overexpress the ?-Klotho protein.
These cells will enable Klothonova, the parties' joint venture (JV), to advance its anti-aging product candidate within the ongoing ?-Klotho development program, following the successful completion of all preparatory activities in February.
This milestone supports the JV's efforts to create a sustainable, cell-based approach to restoring circulating levels of the ?-Klotho "longevity protein" for potential therapeutic benefits in aging and related conditions.
A Master Cell Bank (MCB) is a GMP-compliant, fully characterized, and homogeneous collection of vials derived from a single clone. The MCB is a critical starting material that forms the foundation for the scale-up and production of cell therapies. It serves as an essential resource, ensuring product consistency and reducing risk by safeguarding against contamination, degradation, extraneous agents, and genetic instability. Establishing and maintaining a high-quality MCB, which serves as the primary source for all working cell banks--under Good Manufacturing Practices (GMP) standards positions Avaí Bio and Austrianova for long-term success by supporting a reliable and sustainable supply chain.
The banked cells will ultimately be used to produce the final Cell-in-a-Box® encapsulated cell product, intended for use in innovative cell-based therapies targeting age-related diseases, such as Alzheimer's¹ and cancer², while also advancing anti-aging and longevity treatments.
"We are excited to enter the first step in the production phase of ?-Klotho producing cells as part of our commitment to deliver safe, effective treatments for aging associated diseases," said Chris Winter, Chief Executive Officer of Avaí Bio.
Prof. Walter H. Gunzburg, Chairman of Austrianova, added, "MCBs are a prerequisite for the production of Cell-in-a-Box® encapsulated cell products. They provide the foundation for sustainable production and ensure they meet the highest quality standards."
This is the latest development as part of the JV agreement signed in September 2025, which established Klothonova as a Nevada-based entity, equally owned by Avaí Bio and Austrianova's affiliate, SG Austria Pte. Ltd. The JV focuses on sustainable production of ?-Klotho--known as the "longevity protein" and a key regulatory protein that is well documented for its anti-aging and protective effects on organs--in patients using encapsulated cell-based therapies.
- https://jamanetwork.com/journals/jamaneurology/article-abstract/2844556
- https://pubmed.ncbi.nlm.nih.gov/40004457/
About Avaí Bio, Inc.
Avaí Bio, Inc. is an emerging biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements developing innovative cell-based therapies.
About Austrianova (SGAustria Pte. Ltd.)
Austrianova, based in Singapore, is a leading biotechnology company specializing in cell encapsulation, GMP-grade cell products, and cell line development, backed by over 50 peer-reviewed publications and partnerships with global pharmaceutical and biotech companies.
More information about Avaí Bio can be found at https://www.avaibio.com
You can also follow us on social media at:
https://x.com/AvaiBio
https://www.facebook.com/AvaiBio
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avaí Bio, Inc.
info@avaibio.com
SOURCE Avaí Bio, Inc.
View original content: http://www.newswire.ca/en/releases/archive/March2026/03/c5286.html
FAQ**
How does the establishment of the Master Cell Bank (MCB) for Klotho anti-aging therapy under GMP standards enhance the production capabilities of Avant Technologies Inc. AVAI in the biotechnology sector?
What specific advantages does the partnership between Avant Technologies Inc. AVAI and Austrianova bring to the development of sustainable cell-based therapies for age-related disorders?
Can you elaborate on the expected therapeutic benefits of the Klotho protein in aging and related conditions that Avant Technologies Inc. AVAI aims to target through this joint venture?
How does Avant Technologies Inc. AVAI plan to mitigate risks associated with product consistency and contamination in the production of its Klotho-based therapies using the Master Cell Bank?
**MWN-AI FAQ is based on asking OpenAI questions about Avant Technologies Inc. (OTC: AVAI).
NASDAQ: AVAI
AVAI Trading
-8.43% G/L:
$0.38 Last:
15,633 Volume:
$0.431 Open:
